Peritoneal Delivery of Sodium Pyrophosphate Blocks the Progression of Pre-existing Vascular Calcification in Uremic Apolipoprotein-E Knockout Mice
Gespeichert in:
Verfasser / Beitragende:
[Rodrigo de Oliveira, Loïc Louvet, Bruce Riser, Fellype Barreto, Joyce Benchitrit, Raja Rezg, Sabrina Poirot, Vanda Jorgetti, Tilman Drüeke, Ziad Massy]
Ort, Verlag, Jahr:
2015
Enthalten in:
Calcified Tissue International, 97/2(2015-08-01), 179-192
Format:
Artikel (online)
Online Zugang:
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605521026 | ||
| 003 | CHVBK | ||
| 005 | 20210128100738.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150801xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s00223-015-0020-7 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s00223-015-0020-7 | ||
| 245 | 0 | 0 | |a Peritoneal Delivery of Sodium Pyrophosphate Blocks the Progression of Pre-existing Vascular Calcification in Uremic Apolipoprotein-E Knockout Mice |h [Elektronische Daten] |c [Rodrigo de Oliveira, Loïc Louvet, Bruce Riser, Fellype Barreto, Joyce Benchitrit, Raja Rezg, Sabrina Poirot, Vanda Jorgetti, Tilman Drüeke, Ziad Massy] |
| 520 | 3 | |a Chronic kidney disease (CKD) is generally associated with disturbances of mineral and bone metabolism. They contribute to the development of vascular calcification (VC), a strong, independent predictor of cardiovascular risk. Pyrophosphate (PPi), an endogenous inhibitor of hydroxyapatite formation, has been shown to slow the progression of VC in uremic animals. Since in patients with CKD treatment is usually initiated for already existing calcifications, we aimed to compare the efficacy of PPi therapy with that of the phosphate binder sevelamer, using a uremic apolipoprotein-E knockout mouse model with advanced VCs. After CKD creation or sham surgery, 12-week-old female mice were randomized to one sham group and four CKD groups (n=18-19/group). Treatment was initiated 8weeks after left nephrectomy allowing prior VC development. Uremic groups received either intraperitoneal PPi (high dose, 1.65mg/kg or low dose, 0.33mg/kg per day), oral sevelamer (3% in diet), or placebo treatment for 8weeks. Both intima and media calcifications worsened with time in placebo-treated CKD mice, based on both quantitative image analysis and biochemical measurements. Progression of calcification between 8 and 16weeks was entirely halted by PPi treatment, as it was by sevelamer treatment. PPi did not induce consistent bone histomorphometry changes. Finally, the beneficial vascular action of PPi probably involved mechanisms different from that of sevelamer. Further studies are needed to gain more precise insight into underlying mechanisms and to see whether PPi administration may also be useful in patients with CKD and VC. | |
| 540 | |a Springer Science+Business Media New York, 2015 | ||
| 690 | 7 | |a Apolipoprotein-E knockout mice |2 nationallicence | |
| 690 | 7 | |a Chronic kidney disease |2 nationallicence | |
| 690 | 7 | |a Mineral and bone disorder |2 nationallicence | |
| 690 | 7 | |a Sevelamer hydrochloride |2 nationallicence | |
| 690 | 7 | |a Sodium pyrophosphate |2 nationallicence | |
| 690 | 7 | |a Vascular calcification |2 nationallicence | |
| 700 | 1 | |a de Oliveira |D Rodrigo |u INSERM Unit 1088, UFR de Médecine et de Pharmacie, University of Picardie Jules Verne (UPJV), 1 rue des Louvels, 80037, Amiens, France |4 aut | |
| 700 | 1 | |a Louvet |D Loïc |u INSERM Unit 1088, UFR de Médecine et de Pharmacie, University of Picardie Jules Verne (UPJV), 1 rue des Louvels, 80037, Amiens, France |4 aut | |
| 700 | 1 | |a Riser |D Bruce |u BLR BIO, LLC, 313 54th Street, 53140, Kenosha, WI, USA |4 aut | |
| 700 | 1 | |a Barreto |D Fellype |u INSERM Unit 1088, UFR de Médecine et de Pharmacie, University of Picardie Jules Verne (UPJV), 1 rue des Louvels, 80037, Amiens, France |4 aut | |
| 700 | 1 | |a Benchitrit |D Joyce |u INSERM Unit 1088, UFR de Médecine et de Pharmacie, University of Picardie Jules Verne (UPJV), 1 rue des Louvels, 80037, Amiens, France |4 aut | |
| 700 | 1 | |a Rezg |D Raja |u INSERM Unit 1088, UFR de Médecine et de Pharmacie, University of Picardie Jules Verne (UPJV), 1 rue des Louvels, 80037, Amiens, France |4 aut | |
| 700 | 1 | |a Poirot |D Sabrina |u INSERM Unit 1088, UFR de Médecine et de Pharmacie, University of Picardie Jules Verne (UPJV), 1 rue des Louvels, 80037, Amiens, France |4 aut | |
| 700 | 1 | |a Jorgetti |D Vanda |u Division of Nephrology, São Paulo University, Av. Dr. Arnaldo, 455, 3º andar, sala 3342, CEP 01246-903, São Paulo, SP, Brazil |4 aut | |
| 700 | 1 | |a Drüeke |D Tilman |u INSERM Unit 1088, UFR de Médecine et de Pharmacie, University of Picardie Jules Verne (UPJV), 1 rue des Louvels, 80037, Amiens, France |4 aut | |
| 700 | 1 | |a Massy |D Ziad |u INSERM Unit 1088, UFR de Médecine et de Pharmacie, University of Picardie Jules Verne (UPJV), 1 rue des Louvels, 80037, Amiens, France |4 aut | |
| 773 | 0 | |t Calcified Tissue International |d Springer US; http://www.springer-ny.com |g 97/2(2015-08-01), 179-192 |x 0171-967X |q 97:2<179 |1 2015 |2 97 |o 223 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00223-015-0020-7 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s00223-015-0020-7 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a de Oliveira |D Rodrigo |u INSERM Unit 1088, UFR de Médecine et de Pharmacie, University of Picardie Jules Verne (UPJV), 1 rue des Louvels, 80037, Amiens, France |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Louvet |D Loïc |u INSERM Unit 1088, UFR de Médecine et de Pharmacie, University of Picardie Jules Verne (UPJV), 1 rue des Louvels, 80037, Amiens, France |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Riser |D Bruce |u BLR BIO, LLC, 313 54th Street, 53140, Kenosha, WI, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Barreto |D Fellype |u INSERM Unit 1088, UFR de Médecine et de Pharmacie, University of Picardie Jules Verne (UPJV), 1 rue des Louvels, 80037, Amiens, France |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Benchitrit |D Joyce |u INSERM Unit 1088, UFR de Médecine et de Pharmacie, University of Picardie Jules Verne (UPJV), 1 rue des Louvels, 80037, Amiens, France |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Rezg |D Raja |u INSERM Unit 1088, UFR de Médecine et de Pharmacie, University of Picardie Jules Verne (UPJV), 1 rue des Louvels, 80037, Amiens, France |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Poirot |D Sabrina |u INSERM Unit 1088, UFR de Médecine et de Pharmacie, University of Picardie Jules Verne (UPJV), 1 rue des Louvels, 80037, Amiens, France |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Jorgetti |D Vanda |u Division of Nephrology, São Paulo University, Av. Dr. Arnaldo, 455, 3º andar, sala 3342, CEP 01246-903, São Paulo, SP, Brazil |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Drüeke |D Tilman |u INSERM Unit 1088, UFR de Médecine et de Pharmacie, University of Picardie Jules Verne (UPJV), 1 rue des Louvels, 80037, Amiens, France |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Massy |D Ziad |u INSERM Unit 1088, UFR de Médecine et de Pharmacie, University of Picardie Jules Verne (UPJV), 1 rue des Louvels, 80037, Amiens, France |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Calcified Tissue International |d Springer US; http://www.springer-ny.com |g 97/2(2015-08-01), 179-192 |x 0171-967X |q 97:2<179 |1 2015 |2 97 |o 223 | ||